Phase-directed therapy and cardiac xenograft survival

Journal of Surgical Research

Volumn 72, Issue 1, 1997, Pages 84-88

  Lin, Hua ^a   Gastman, Brian R ^a   Wei, Ru Qi ^a   Kunkel, Steven L ^a   Gordon, David ^a   Bolling, Steven F ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN M; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYRIAN HAMSTER; XENOGRAFT; XENOTRANSPLANTATION;

EID: 0031239763     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5145     Document Type: Article

References (30)

1. McManus R. P., O'Hair D. P., Beitzinger J. M. Patients who die awaiting heart transplantation. J. Heart Lung Transplant. 12:1991;159.
2. Bunjes D., Hardt C., Rollinghoff M., Wagner H. Cyclosporine A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin-1 and interleukin-2. Eur. J. Immunol. 11:1981;657.
3. Kahan B. D., Charles T., Van Buren. Clinical and experimental studies with cyclosporine in renal transplantation. Surgery. 97:1985;125.
4. Monde M., Valdivia L. A., Gotoh M., Kubota N., Hasuike Y., Nakano Y., Okamura J., Mori T. A crucial effect of splenectomy on prolonging cardiac xenograft survival in combination with cyclosporine. Surgery. 105:1989;535.
5. Ghaffar A., Sigel M. M., Huggins E. M. Jr. Resistance of helper T lymphocytes to cyclophosphamide. Int. J. Immunopharmacol. 7:1985;449.
6. Turk J. L., Poulter L. W. Effects of cyclophosphamide on lymphoid tissues labeled with 5-iodo-2-deoxyurisine-125I and 51Cr. Int. Arch. Allergy. 43:1972;620.
7. Catena M., Lattanzio G., Maggiano N., Musiani P., Ferla G. Timing of spleen activation in rats treated with cyclophosphamide (CyP): Its role in a hamster-to-rat heterotopic heart xenotransplantation (HHX) model. Transplant. Proc. 26:1994;1182.
8. Bolling S. F., Kunkel S. L., Lin H. Prolongation of cardiac allograft survival in rats by anti-TNF and cyclosporine combination therapy. Transplantation. 53:1992;283.
9. Lin H., Chensue S. W., Strieter R. M., Remick D. G., Gallagher K. P., Bolling S. F., Kunkel S. L. Antibodies against tumor necrosis factor prolong cardiac allograft survival in the rat. J. Heart Lung Transplant. 11:1992;330.
10. Imagawa D. K., Millis J. M., Seu P. The role of tumor necrosis factor in allograft rejection. Transplantation. 51:1991;57.
11. Starzl T. E., Valdivia L. A., Murase N., Demetris A. J. The biological basis and strategies for clinical xenotransplantation. Immunol. Rev. 141:1994;213.
12. Lim S. M. L., Li Sq, Wee A. Both concordant and discordant heart xenografts are rejected by athymic (nude) rats with the same tempo as in T cell competent animals. Transplant. Proc. 23:1991;581.
13. Van Den J. B., Aspinall B. R., White D. J. G. Hamster to rat xenografts are not rejected primarily by rat T cells. Transplant. Proc. 23:1991;2277.
14. Steinbruchel D. A., Nielsen B., Salomon S., Kemp E. Sequential, morphological and antidonor antibody analysis in a hamster-to-rat heart transplantation model. Transplant. Int. 5:1992;38.
15. Murase N., Starzl T. E., Demetris A. J., Valdivia L., Tanabe M., Cramer D., Makowka L. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation. 55:1993;701.
16. Catena M., Lattanzio G., Maggiano N., Musiani P., Ferla G. Timing of spleen activation in rats treated with cyclophosphamide (CyP): Its role in a hamster-to-rat heterotopic heart xenotransplantation (HHX) model. Transplant. Proc. 26:1994;1182.
17. Hasan R. I. R., Sriwatanawangosa V., Wallwork J., White D. J. G. Graft adaptation in hamster-to-rat cardiac xenografts. Transplant. Proc. 26:1994;1282.
18. Thomas F., Araneda D., Quarantillo P. Long-term survival of disparate cardiac xenografts: Induction of tolerance and humoral accommodation. Transplant. Proc. 26:1994;1220.
19. Valdivia L. A., Monden M., Gotoh M. Evidence that deoxyspergualin prevents sensitization and first-set cardiac xenograft rejection in rats by suppression of antibody formation. Transplantation. 50:1990;132.
20. Nakajma K., Sakamoto K., Ochiai T. Effects of 15-deoxyspurgalin and FK 506 on the histology and survival of hamster-to-rats cardiac xenotransplantation. Transplantation. 21:1989;546.
21. Knechtle S. J., Halperin E. C., Bollinger R. R. Xenograft survival in two species combination using total lymphoid irradiation and cyclospSporin. Transplantation. 43:1987;173.
22. Nawroth P. P., Waldherr R., Zhang Y. M., Lin J. Mechanism of endothelial cell activation. Transplant. Proc. 25:1993;2052.
23. Bach F. H., Blakely M. L., Van der Werf W. J. Xenotransplantation: Problems posed by endothelial cell activation. Transplant. Proc. 26:1994;1029.
24. Pober J. S. Cytokine-mediated activation of vascular endothelium. Physiology and pathology. Am. J. Pathol. 133:1988;426.
25. Pober J. S. TNF as an activator of vascular endothelium. Ann. Inst. Pasteur. Immunol. 139:1988;317.
26. Pober J. S., Cotran R. S. Cytokines and endothelial cell biology. Physiol. Rev. 70:1990;427.
27. Mantovani A., Bussolino F., Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 6:1992;2591.
28. Mandrup-Poulsen T., Helqvist S., Wogensen L. D. Cytokines and free radicals as effector molecules in the destruction of pancreatic beta cell. Curr. Topic. Microbiol. Immunol. 164:1990;169.
29. Paleolog E. M., Delasalle S. A., Buurman W. A., Feldmann M. Functional activities of receptors for tumor necrosis factor-alpha on human vascular endothelial cells. Blood. 84:1994;2578.
30. Wei R. Q., Lin H., Chen G. H., Beer D. G., Kunkel S. L., Bolling S. F. Inhibition of tumor necrosis factor production by lymphocytes from anti-TNF antibody-treated, cardiac-allografted rats. J. Surg. Res. 56:1994;601.